Emerging treatment options for refractory angina pectoris: Ranolazine, shock wave treatment, and cell-based therapies

Reviews in Cardiovascular Medicine

Volumn 15, Issue 1, 2014, Pages 31-37

  Gennari, Marco ^a   Gambini, Elisa ^a   Bassetti, Beatrice ^a   Capogrossi, Maurizio ^b   Pompilio, Giulio ^a  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Coronary artery disease; Refractory angina pectoris; Stem cell therapy

Indexed keywords

RANOLAZINE; ACETANILIDE DERIVATIVE; PIPERAZINE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT;

ANGINA PECTORIS; ANGIOGENESIS; BONE MARROW CELL; CELL THERAPY; CELL TYPE; CLINICAL PRACTICE; ENDOTHELIAL PROGENITOR CELL; EXTRACORPOREAL LITHOTRIPSY; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; REFRACTORY ANGINA PECTORIS; REGENERATIVE MEDICINE; REVIEW; SUBSTITUTION THERAPY; THORACOTOMY; ANIMAL; ENDOTHELIUM CELL; PATHOLOGY; PATHOPHYSIOLOGY; RADIATION; REGENERATION; STEM CELL TRANSPLANTATION; TRANSPLANTATION; TREATMENT OUTCOME;

ACETANILIDES; ANGINA PECTORIS; ANIMALS; ENDOTHELIAL CELLS; HIGH-ENERGY SHOCK WAVES; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PIPERAZINES; REGENERATION; SODIUM CHANNEL BLOCKERS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84901921259     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0672     Document Type: Review

References (24)

1. DeJongste MJ, Tio RA, Foreman RD. Chronic therapeutically refractory angina pectoris. Heart. 2004;90:225-230. (Pubitemid 38147169)
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
3. Andréll P, Ekre O, Grip L, et al. Fatality, morbidity and quality of life in patients with refractory angina pectoris. Int J Cardiol. 2011;147:377-382.
4. US Food and Drug Administration Web site. Safety. Ranexa (ranolazine) extended-release tablets. http://www.fda.gov/Safety/MedWatch/Safety Information/ucm229433.htm. Accessed January 21, 2014.
5. Wang Y, Guo T, Cai HY, et al. Cardiac shock wave therapy reduces angina and improves myocardial function in patients with refractory coronary artery disease. Clin Cardiol. 2010;33:693-699.
6. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95:311-316. (Pubitemid 40164531)
7. Barsotti MC, Di Stefano R, Spontoni P, et al. Role of endothelial progenitor cell mobilization after percutaneous angioplasty procedure. Curr Pharm Des. 2009;15:1107-1122.
8. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967. (Pubitemid 27087709)
9. Sieveking DP, Ng MK. Cell therapies for therapeutic angiogenesis: back to the bench. Vasc Med. 2009;14:153-166.
10. Pompilio G, Gennari M, Gambini E, et al. Refractory angina pectoris: focus on cell therapy. In: Pešek K, ed. Atherosclerotic Cardiovascular Disease. Rijeka, Croatia: InTech; 2011:107-125.
11. Greenwood HL, Singer PA, Downey GP, et al. Regenerative medicine and the developing world. PLoS Med. 2006;3:e381.
12. Burba I, Devanna P, Pesce M. When cells become a drug. Endothelial progenitor cells for cardiovascular therapy: aims and reality. Recent Pat Cardiovasc Drug Discov. 2010;5:1-10.
13. Hung HS, Shyu WC, Tsai CH, et al. Transplantation of endothelial progenitor cells as therapeutics for cardiovascular diseases. Cell Transplant. 2009;18:1003-1012.
14. + stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007;115:3165-3172.
15. Pesce M, Burba I, Gambini E, et al. Endothelial and cardiac progenitors: boosting, conditioning and (re) programming for cardiovascular repair. Pharmacol Ther. 2011;129:50-61.
16. Pompilio G, Steinhoff G, Liebold A, et al. Direct minimally invasive intramyocardial injection of bone marrow-derived AC1331 stem cells in patients with refractory ischemia: preliminary results. Thorac Cardiovasc Surg. 2008;56:71-76. (Pubitemid 351453913)
17. Attanasio S, Schaer G. Therapeutic angiogenesis for the management of refractory angina: current concepts. Cardiovasc Ther. 2011;29:e1-e11.
18. TenVaarwerk IA, Jessurun GA, DeJongste MJ, et al. Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris. The Working Group on Neurocardiology. Heart. 1999;82:82-88. (Pubitemid 29309241)
19. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95:343-353. (Pubitemid 39100452)
20. Yoon CH, Hur J, Park KW, et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation. 2005;112:1618-1627. (Pubitemid 41324524)
21. Young PP, Vaughan DE, Hatzopoulos AK. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog Cardiovasc Dis. 2007;49:421-429. (Pubitemid 46693946)
22. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44:192-199. (Pubitemid 38982162)
23. Chaitman BR, Pepine CJ, Parker J, et al Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with chronic severe angina: a randomized controlled trial. JAMA. 2004;291:309-316. (Pubitemid 38101603)
24. Tse HF, Kwong YL, Chan JK, et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003;361:47-49. (Pubitemid 36050963)